Novartis Cosentyx gets FDA OK for child, adolescent psoriasis

 Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo(1)

- The safety profile of Cosentyx in pediatric patients with plaque psoriasis was demonstrated in two Phase III trials(1)

- Plaque psoriasis is a chronic, inflammatory disease that may impact up to 350,000 children worldwide, with onset most common during adolescence(2,3)

https://www.prnewswire.com/news-releases/novartis-cosentyx-receives-fda-approval-for-treatment-of-children-and-adolescents-with-moderate-to-severe-plaque-psoriasis-301303365.html